TG Therapeutics, Inc. (TGTX): Price and Financial Metrics


TG Therapeutics, Inc. (TGTX): $5.17

0.12 (+2.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TGTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TGTX POWR Grades


  • TGTX scores best on the Growth dimension, with a Growth rank ahead of 62.76% of US stocks.
  • The strongest trend for TGTX is in Stability, which has been heading down over the past 179 days.
  • TGTX's current lowest rank is in the Stability metric (where it is better than 2.79% of US stocks).

TGTX Stock Summary

  • With a price/sales ratio of 225.47, Tg Therapeutics Inc has a higher such ratio than 98.7% of stocks in our set.
  • As for revenue growth, note that TGTX's revenue has grown 4,300.66% over the past 12 months; that beats the revenue growth of 99.6% of US companies in our set.
  • In terms of volatility of its share price, TGTX is more volatile than 94.76% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Tg Therapeutics Inc are INMB, BBIO, VIR, FIXX, and ARGX.
  • TGTX's SEC filings can be seen here. And to visit Tg Therapeutics Inc's official web site, go to www.tgtherapeutics.com.

TGTX Valuation Summary

  • In comparison to the median Healthcare stock, TGTX's price/sales ratio is 42050% higher, now standing at 1601.7.
  • TGTX's price/earnings ratio has moved down 7.9 over the prior 138 months.
  • TGTX's EV/EBIT ratio has moved down 5.4 over the prior 138 months.

Below are key valuation metrics over time for TGTX.

Stock Date P/S P/B P/E EV/EBIT
TGTX 2021-08-31 1601.7 10.1 -11.2 -10.3
TGTX 2021-08-30 1580.4 10.0 -11.1 -10.2
TGTX 2021-08-27 1601.7 10.1 -11.2 -10.3
TGTX 2021-08-26 1491.1 9.4 -10.4 -9.6
TGTX 2021-08-25 1534.2 9.7 -10.8 -9.9
TGTX 2021-08-24 1520.6 9.6 -10.7 -9.8

TGTX Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -62.38%.
  • Its 5 year price growth rate is now at 157.91%.
  • Its 3 year net income to common stockholders growth rate is now at -168.58%.
Over the past 34 months, TGTX's revenue has gone up $6,537,000.

The table below shows TGTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 6.689 -295.634 -348.101
2021-09-30 4.406 -260.751 -342.98
2021-06-30 2.414 -250.082 -344.506
2021-03-31 0.907 -233.747 -318.893
2020-12-31 0.152 -214.507 -279.381
2020-09-30 0.152 -192.874 -230.735

TGTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TGTX has a Quality Grade of D, ranking ahead of 7.5% of graded US stocks.
  • TGTX's asset turnover comes in at 0.005 -- ranking 411th of 681 Pharmaceutical Products stocks.
  • TMBR, ATRA, and EVOK are the stocks whose asset turnover ratios are most correlated with TGTX.

The table below shows TGTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 0.881 -27.668
2021-03-31 0.002 0.847 -42.516
2020-12-31 0.000 1.000 -36.140
2020-09-30 0.001 1.000 -86.159
2020-06-30 0.001 1.000 -22.399
2020-03-31 0.001 1.000 -12.310

TGTX Price Target

For more insight on analysts targets of TGTX, see our TGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.33 Average Broker Recommendation 1.44 (Moderate Buy)

TGTX Stock Price Chart Interactive Chart >

Price chart for TGTX

TGTX Price/Volume Stats

Current price $5.17 52-week high $41.00
Prev. close $5.05 52-week low $4.73
Day low $4.74 Volume 3,397,200
Day high $5.26 Avg. volume 2,642,769
50-day MA $7.87 Dividend yield N/A
200-day MA $18.23 Market Cap 746.73M

TG Therapeutics, Inc. (TGTX) Company Bio


TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.


TGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

TGTX Latest Social Stream


Loading social stream, please wait...

View Full TGTX Social Stream

Latest TGTX News From Around the Web

Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

AdaptHealth Corp. (AHCO) Q4 Earnings Miss Estimates

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update

Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ETNEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2021 and provide a business outlook for 2022. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-2

Yahoo | February 24, 2022

2 Wildly Oversold Stocks That Could Explode Higher

The stock market is often an exercise in reverse psychology. When a stock goes up, investors instinctively want to get a piece of the action. Likewise, when a stock drifts to the bottom, the natural inclination is to run away. But any investor worth their salt knows they need to battle against those natural impulses as the bottom is often the most appealing starting point; because it is from there that the real gains are made.

Marty Shtrubel on TipRanks | February 15, 2022

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 24 – 26, 2022, in West Palm Beach, Florida. Abstracts are now available online and can be access

Yahoo | February 15, 2022

Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe

TG Therapeutics (TGTX) is giving the biopharma market the scare of its life, with the FDA looking more and more likely to come up with a negative opinion on the approval of Ublituximab+Umbralisib (Ukoniq), also known as U2, in Chronic Lymphocytic Lymphoma or CLL. The FDA’s beef is directed against...

Avisol Capital Partners on Seeking Alpha | February 8, 2022

Read More 'TGTX' Stories Here

TGTX Price Returns

1-mo -22.95%
3-mo -47.78%
6-mo -77.87%
1-year -85.17%
3-year -25.07%
5-year -57.10%
YTD -72.79%
2021 -63.48%
2020 368.65%
2019 170.73%
2018 -50.00%
2017 76.34%

Continue Researching TGTX

Want to see what other sources are saying about Tg Therapeutics Inc's financials and stock price? Try the links below:

Tg Therapeutics Inc (TGTX) Stock Price | Nasdaq
Tg Therapeutics Inc (TGTX) Stock Quote, History and News - Yahoo Finance
Tg Therapeutics Inc (TGTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7213 seconds.